Yi-Li Min

Yi-Li Min currently holds the position of Associate Director at Vertex Pharmaceuticals, leading a project team to develop AAV-based gene editing therapy for neuromuscular disease. With a background in genetics, molecular virology, and extensive research experience at various organizations, Yi-Li has contributed significantly to the field of biotechnology. From investigating Crohn's disease-associated genes to developing therapeutic antibodies, Yi-Li's expertise and leadership have made a profound impact in the biotech industry.